Home
    • Plans Blog Contact
    ProPhase Labs Inc logo

    ProPhase Labs Inc

    PRPH
    Last price US$0.0586
    Market cap US$540000.0
    12M price change N/A
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Seneca Foods Corp BSENEB Industry peer Kraft Heinz CoKHC Industry peer Hostess Brands IncTWNK Industry peer Kimberly-Clark CorporationKMB Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    ProPhase Labs Inc Overview

    Industry: Food & Tobacco

    Sector: Consumer Non-Cyclicals

    ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for ProPhase Labs Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Nov 19, 2025

    Quarterly result summary

    Revenue was $0.9M (-36% YoY). Net loss was -$6,839.

    Revenue $0.9M -36% YoY
    Net loss -$6,839 reported

    What changed

    • Revenue -36% YoY to $0.9M.

    Guidance / outlook

    The Company expects that proceeds generated through Crown Medical Collections’ recovery efforts will provide substantial non-dilutive capital to advance BE-Smart commercialization, support Nebula Genomics’ growth, and fund other key initiatives.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q/A Jul 09, 2026 SEC filing 10-Q/A Jul 07, 2026 SEC filing 10-Q Jun 30, 2026 SEC filing 10-K Jun 01, 2026 SEC filing 10-Q Nov 19, 2025 SEC filing 8-K Nov 19, 2025 SEC filing 10-Q Aug 13, 2025 SEC filing 8-K Aug 13, 2025 Earnings release Earnings release Aug 13, 2025 SEC filing 10-Q May 20, 2025 Earnings release Earnings release May 20, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    No qualified company news in the last 14 days

    No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

    Earnings Per Share

    Score 3.00/5
    ProPhase Labs Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Kimberly-Clark Corporation Coca-Cola Co Seneca Foods Corp B
    In Food & Tobacco industry , Seneca Foods Corp B , Kraft Heinz Co , Hostess Brands Inc are companies with high ratings.

    Return on Equity

    Score 0.92/5
    ProPhase Labs Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Kimberly-Clark Corporation Coca-Cola Co Seneca Foods Corp B
    ProPhase Lab... PRPH US$540000
    Kimberly-Cla... KMB US$37.4b
    Coca-Cola Co KO US$359.3b
    Seneca Foods... SENEB US$1.1b

    Net Margin

    Score 0.92/5
    ProPhase Labs Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Kimberly-Clark Corporation Coca-Cola Co Seneca Foods Corp B
    ProPhase Lab... PRPH US$540000
    Kimberly-Cla... KMB US$37.4b
    Coca-Cola Co KO US$359.3b
    Seneca Foods... SENEB US$1.1b

    Share Buyback

    In Food & Tobacco industry , Seneca Foods Corp B , Kraft Heinz Co , Hostess Brands Inc are companies with high ratings.

    Leverage

    Score 3.77/5
    ProPhase Labs Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Kimberly-Clark Corporation Coca-Cola Co Seneca Foods Corp B , also exhibit high scores.
    ProPhase Lab... PRPH US$540000
    Kimberly-Cla... KMB US$37.4b
    Coca-Cola Co KO US$359.3b
    Seneca Foods... SENEB US$1.1b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    ProPhase Labs Inc logo

    ProPhase Labs Inc

    US$0.0586

    US$540000.0

    -16.29%

    N/A